Adjunctive therapy in sepsis: A critical analysis of the clinical trial programme

British Medical Bulletin

Volumn 55, Issue 1, 1999, Pages 212-225

  Cohen, J ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ANTIBODY;

CLINICAL TRIAL; HUMAN; IMMUNOTHERAPY; METHODOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SEPSIS;

ENDOTOXINS; HUMANS; IMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032980120     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1258/0007142991902222     Document Type: Review

References (45)

1. Appelmelk BJ, Cohen J: The protective role of antibodies to the lipopolysaccharide core region. In: Morrison DC, Ryan JL (eds) Bacterial endotoxic lipopolysaccharides, vol II. New York: CRC Press, 1992; 411-28
2. Glauser M-P, Heumann D, Baumgartner J-D et al. Pathogenesis and potential strategies for prevention and treatment of septic shock: an update. Clin Infect Dis 1994; 18 (Suppl 2): S205-16
3. Lynn WA, Cohen J. Adjunctive therapy for septic shock: a review of experimental approaches. Clin Infect Dis 1995; 20: 143-58
4. Morrison DC. Bacterial endotoxins and pathogenesis. Rev Infect Dis 1983; 5: S733-47
5. Ziegler EJ, McCutchan JA, Fierer J et al. Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982; 307: 1225-30
6. Baumgartner J-D, Glauser M-P, McCutchan JA et al. Prevention of Gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet 1985; ii: 59-63
7. Ziegler EJ, Fisher Jr CJ, Sprung C et al. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1991; 324: 429-36
8. McCloskey RV, Straube RC, Sanders C et al. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double blind, placebo-controlled trial. Ann Intern Med 1994; 121: 1-5
9. Baumgartner J-D, Heumann D, Gerain J et al. Association between protective efficacy of antilipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies and core LPS antibodies. J Exp Med 1990; 171: 889-96
10. Giroir BP, Quint PA, Barton P et al. Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis. Lancet 1997; 350: 1439-43
11. Pajkrt D, Doran JE, Koster F et al. Anti-inflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996; 184: 1601-8
12. Reinhart K, Wiegand-Löhnert C, Grimminger F et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996; 24: 733-12
13. Haak-Frendscho M, Marsters SA, Mordenti J et al. Inhibition of TNF by a TNF receptor immunoadhesin. Comparison to an anti-TNF monoclonal antibody. J Immunol 1994; 152: 1347-53
14. Fisher Jr CJ, Agosti JM, Opal SM et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996; 334: 1697-702
15. Evans TJ, Moyes D, Carpenter A et al. Protective effect of 55-but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of Gram-negative sepsis. J Exp Med 1994; 180: 2173-9
16. Abraham E, Glauser M-P, Butler T et al. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. JAMA 1997; 277: 1531-8
17. Evans TJ, Carpenter A, Silva AT et al. Inhibition of nitric oxide synthase in experimental Gram negative sepsis. J Infect Dis 1994; 169: 343-9
18. Bone RC, Fisher Jr CJ, Clemmer TP et al. Sepsis syndrome: a valid clinical entity. Crit Care Med 1989; 17: 389-93
19. Bone RC, Balk RA, Cerra FB et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-55
20. Vincent J-L. Sepsis and septic shock: update on definitions. In: Reinhart K, Eyrich K et al (eds) Sepsis. Current perspectives in pathophysiology and therapy. Berlin: Springer, 1994; 3-15
21. Knaus WA, Wagner DP, Harrell FE. What determines prognosis in sepsis? In: Sibbald WJ, Vincent J-L (eds) Clinical trials for the treatment of sepsis. Berlin: Springer, 1995; 141-56
22. Lynn WA, Cohen J. Microbiological requirements for studies of sepsis. In: Sibbald WJ, Vincent J-L (eds) Clinical trials for the treatment of sepsis. Update in emergency medicine and intensive care 19. Berlin: Springer, 1995; 71-85
23. Kreger BE, Craven DE, McCabe WR. Gram-negative bacteremia IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 1980; 68: 344-55
24. Marshall JC, Lowry SF. Evaluation of the adequacy of source control. In: Sibbald WJ, Vincent J-L (eds) Clinical trials for the treatment of sepsis. Berlin: Springer, 1995; 329-44
25. Doig GS, Rochon J. Statistical considerations for the design of the optimal clinical trial. In: Sibbald WJ, Vincent J-L (eds) Clinical trials for the treatment of sepsis. Berlin: Springer, 1995; 345-53
26. Sprung C, Finch RG, Thijs LG et al. International sepsis trial (INTERSEPT): role and impact of a clinical evaluation committee. Crit Care Med 1996; 24: 1441-7
27. Hébert PC. Mortality as an outcome in sepsis trials. Sepsis 1997; 1: 35-40
28. Cohen J. Is there a role for surrogate markers in the evaluation of sepsis trials? In: Vincent J-L (ed) Yearbook of intensive care and emergency medicine. Berlin: Springer, 1998; 257-62
29. Intravenous Immunoglobulin Collaborative Study Group. Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl J Med 1992; 327: 234-40
30. The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin. Arch Intern Med 1994; 154: 2484-91
31. Greenman RL, Schein RM, Martin MA et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram negative sepsis. JAMA 1991; 266: 1097-102
32. Bone RC, Balk RA, Fein AM et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 1995; 23: 994-1006
33. Panacek EA, MacArthur RD, Johnson SB. Results of a phase III clinical trial of the human monoclonal antibody Mab-T88 versus placebo in Gram negative sepsis. Abstracts of the Society of Critical Care Medicine, 1995
34. Abraham E, Wunderink R, Silverman H et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. JAMA 1995; 273: 934-41
35. Cohen J, Carlet J, INTERSEPT Study Group. INTERSEPT: an international multicenter placebo-controlled trial of monoclonal antibody to human TNF-α in patients with sepsis. Crit Care Med 1996; 24: 1431-40
36. Abraham E, Anzueto A, Gutierrez G et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet 1998; 351: 929-33
37. Fisher Jr CJ, Dhainaut JF, Opal SM et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. JAMA 1994; 271: 1836-43
38. Opal SM, Fisher Jr CJ, Dhainaut JF et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997; 25: 1115-24
39. Dhainaut JF, Tenaillon A, Le Tulzo Y et al. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 1994; 22: 1720-8
40. Gourlay ML, Dhainaut JF, Tenaillon A et al. Confirming phase III clinical trial to study the efficacy of a PAF antagonist, BN 52021, in reducing mortality of patients with severe Gram negative sepsis. Shock 1995; 3 (Suppl): 65
41. Bernard GR, Wheeler AP, Russell JA et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 1997; 336: 912-8
42. Yu M, Tomasa G. A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit Care Med 1993; 21: 1635-42
43. Fourrier F, Chopin C, Huart J-J et al. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993; 104: 882-8
44. Fein AM, Bernard GR, Criner GJ et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. JAMA 1997; 277: 482-7
45. Spies CD, Reinhart K, Witt I et al. Influence of N-acetylcysteine on indirect indicators of tissue oxygenation in septic shock patients: results from a prospective, randomized, double-blind study. Crit Care Med 1994; 22: 1738-46